IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Amgen to acquire Onyx Pharmaceuticals for $10.4 billion

8:55 AM MDT | August 26, 2013 | Natasha Alperowicz

Amgen (Thousand Oaks, CA), the world’s largest independent biotechnology company; and Onyx Pharmaceuticals announced on Sunday that their boards of directors have unanimously approved a transaction for Amgen to acquire all of the outstanding shares of Onyx for $125/share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash.    Onyx is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. Onyx has an...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa